Navigation Links
Preventing tuberculosis reactivation
Date:10/18/2007

Tuberculosis (TB) is the leading cause of death due to infectious disease in the world today. It is estimated that 2 billion people are currently infected, and although most people have latent infection, reactivation can occur. This paper by Denise Kirschner and colleagues, publishing in PLoS Computational Biology, conducts virtual clinical trials to examine the causes of reactivation.

Tumor necrosis factor alpha (TNF) is a protein that facilitates cellcell communication during an inflammatory immune response. Animal models have shown that TNF is vital for control of TB infection. However, anti-TNF treatments are common therapies for treating autoimmune diseases, and this can cause an unwanted side effect of reactivating latent TB. Kirschner has developed a computational model that can quickly perform virtual clinical trials to predict why reactivation occurs and why it happens differently with different drugs.

Their results suggest that anti-TNF therapy is highly likely to lead to many incidents of TB if used in areas where exposure to the TB pathogen is probable. However, they also propose that a TNF-modulating agent could be developed that could balance the requirement for reduction of inflammation with the necessity to maintain resistance to infection and microbial disease. In the mean time, modifying the dosage and timing of anti-TNF treatment could prevent reactivation, as could a complete regimen of antibiotic treatment for TB prior to anti-TNF treatment.


'/>"/>

Contact: Johanna Dehlinger
press@plos.org
415-624-1202
Public Library of Science
Source:Eurekalert

Page: 1

Related biology news :

1. Undesirable expatriates: Preventing the spread of invasive animals
2. Size matters: Preventing large mammal extinction
3. Controlling wildlife trade key to preventing health crises, study says
4. Preventing a pandemic: Study suggests strategies for containing a flu outbreak
5. Free HIV tests cheaper than charging when goal is preventing AIDS
6. UC Davis study finds HIV hiding from drugs in gut, preventing immune recovery
7. Pollution threatens coral health by preventing lesions from healing, UCF study shows
8. Opening windows may be the best way of preventing transmission of airborne infection
9. Scientists find missing enzyme for tuberculosis iron scavenging pathway
10. New vaccine protects more effectively against tuberculosis
11. Boosting The BCG Vaccine To Beat Tuberculosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
(Date:2/28/2017)...  EyeLock LLC, ein marktführendes Unternehmen im Bereich ... Lösung zur Iris-Erkennung auf der neuesten Mobilplattform ... dem Mobile World Congress 2017 (27. Februar ... 3, Stand 3E10, vorstellen. Der ... – eine Kombination aus Hardware, Software und ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is pleased to ... presented by The Conference Forum in Boston on April 3-4, 2017. The CTC conference ... clinical trial outcomes and bring them closer to the patient. Clinical Trial Collaborations also ...
(Date:3/27/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... today announced that it is now offering a 3 ... who want to have their DarioHealth products reimbursed by ... agreements with partners across the U.S. who will be ... will supply and bill the customer,s insurance for their ...
(Date:3/24/2017)... MOSCOW and ROCKVILLE, Md. ... portfolio company of Maxwell Biotech Venture Fund (MBVF), today ... of SQ109 added to the standard drug therapy regimen ... a new small molecule drug discovered by scientists at ... US National Institutes of Health. A ...
Breaking Biology Technology: